Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 839-843

  Lazarczyk, Maciej ^a   Grzela, Tomasz ^a,b   Niderla, Justyna ^a   Golab, Jakub ^c   Korczak Kowalska, Grazyna ^d   Oldak, Monika ^a   Skopinski, Piotr ^c,e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Veterans Central Hospital   (Poland)

^c Department of Histology and Embryology   (Poland)

^d UNIVERSITY OF WARSAW   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cytotoxicity; Inflammation; Pentoxifylline; Tumor

Indexed keywords

PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL SURVIVAL; COLON TUMOR; CYTOTOXICITY; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MONONUCLEAR CELL; MOUSE; PATHOLOGY; SPLEEN; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANIMALS; CELL SURVIVAL; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED BALB C; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; SPLEEN; TUMOR CELLS, CULTURED;

EID: 1542472983     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.839     Document Type: Article

References (27)

1. Mueller R: On the therapy of disturbances of blood fluidity. Angiology 1: 226-234, 1985.
2. Aviado DM and Porter JM: Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297-307, 1984. (Pubitemid 15181910)
3. Skudicky D, Bergemann A, Sliwa K, Candy G and Sareli P: Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and Carvedilol. Circulation 97: 19-22, 1998.
4. Ducloux D, Bresson-Vautrin C and Chalopin J: Use of pentoxifylline in membranous nephropathy. Lancet 357: 1672-1673, 2001. (Pubitemid 32568243)
5. Gorson DM: Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases. Diabetes Care 21: 2190-2191, 1998.
6. Johnson FE, Harrison BR, McKirgan LW, Raju PI, Roy TK and Virgo KS: A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases. Int J Oncol 13: 801-805, 1998. (Pubitemid 28435358)
7. Li YX, Sun LQ, Weber-Johnston K, Paschoud N and Coucke PA: Potentiation of cytotoxicity and radiosensitisation of (E)-2-deoxy-2′-(fluoromethylene) cytydine by pentoxifylline in vitro. Int J Cancer 80: 155-160, 1999. (Pubitemid 28559792)
8. Dominguez-Jimenez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F and Gonzalez-Amaro R: Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol 71: 588-596, 2002.
9. Van Furth AM, Verhard-Seijmonsbergen EM, van Furth R and Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes. Immunology 91: 193-196, 1997. (Pubitemid 27261561)
10. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G and Karp CL: Inhibition of human interleukin-12 production by pentoxifylline. Immunology 91: 197-203, 1997. (Pubitemid 27261562)
11. Thanhauser A, Reiling N, Bohle A, et al: Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 80: 151-156, 1993. (Pubitemid 23284204)
12. Lazarczyk M, Grzela T, Korczak-Kowalska G, Niderla J, Oldak M, Jozwiak J and Skopinski P: Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep 9: 423-426, 2002.
13. Lin Y, Goebels J, Rutgerts O, Kasran A, van Gool S, Ceuppens J, Schonharting M and Waer M: Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities. Transplantation 63: 1813-1818, 1997. (Pubitemid 27278957)
14. Funk JO, Ernst M, Schonharting M and Zabel P: Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporine A. Int J Immunopharmacol 17: 1007-1016, 1995. (Pubitemid 26097583)
15. Aragona M, Maisano R, Panetta S, Giudice A, Morelli M, La Torre I and La Torre F: Telomere length maintenance in aging and carcinogenesis. Int J Oncol 17: 981-989, 2000.
16. Pathak S, Multani AS, Furlong CL and Sohn SH: Telomere dynamics, aneuploidy, stem cells and cancer. Int J Oncol 20: 637-641, 2002.
17. Engelhardt M and Martens UM: The implication of telomerase activity and telomere stability for replicative aging and cellular immortality. Oncol Rep 5: 1043-1052, 1998. (Pubitemid 28372558)
18. Okamoto T: Pentoxifylline inhibits anti-Fas antibody-induced hepatitis by affecting downstream of CPP32-like activity in mice. Int J Mol Med 4: 601-603, 1999.
19. Shirin H, Bruck R, Aeed H, et al: Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor alpha levels and inhibiting adhesion of T lymphocytes to extracellular matrix. J Hepatol 29: 60-67, 1998. (Pubitemid 28307984)
20. Golab J, Stoklosa T, Zagozdzon R, et al: G-CSF preventes the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 9: 63-69, 1997. (Pubitemid 28125766)
21. Sibtain A, Hill S, Goodchild K, et al: The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiother Oncol 62: 69-76, 2002. (Pubitemid 34121951)
22. Vaupel P and Hockel M: Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol 17: 869-879, 2000.
23. Ikeda Y, Koyanagi N, Mori M, et al: Increased incidence of proximal colon cancer in the elderly. J Clin Gastroenterol 23: 105-108, 1996. (Pubitemid 26296290)
24. Fingert HJ, Pu AT, Chen ZY, Googe PB, Alley MC and Pardee AB: In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res 48: 4375-4381, 1988.
25. Kim SH, Khil MS, Ryu S and Kim JH: Enhancement of radiation response on human carcinoma cell lines in culture by pentoxifylline. Int J Radiat Oncol 25: 61-65, 1993. (Pubitemid 23029774)
26. Theron T, Binder A, Verheye-Dua F and Böhm L: The role of G2-block abrogation, DNA doublestrand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int J Radiat Biol 76: 1197-1208, 2000.
27. Binder AB, Serafin AM and Bohm LJ: Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Radiat Res 154: 640-649, 2000.